Status: Not yet recruiting
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
This is an open-label, multi-center Phase II study of fluzoparib combined with bevacizumab for maintenance therapy after first-line platinum-containing chemotherapy in patients with BRCA wild-type advanced ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib plus bevacizumab.
Participants needed: 44
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Oct 2, 2023Locations: 1
Eligibility criteria
Signed informed consent and ability to comply with treatment and follow-up. [+18]
Previous (within 5 years) or concurrent with other uncured malignant tumors, exc... [+17]